According to the 2023 Journal Citation Reports released by Clarivate Analytics on June 20, 2024, four English journals published by West China Hospital—Signal Transduction and Targeted Therapy (STTT), Journal of Evidence Based Medicine (JEBM), Precision Clinical Medicine (PCM), and Acta Epileptologica (AE)—have all received impact factors for 2023, with Acta Epileptologica achieving this score for the first time.

 

STTT has an impact factor of 40.8, ranking 3rd among 313 journals in the Biochemistry & Molecular Biology category and 5th among 205 journals in the Cell Biology category. JEBM has an impact factor of 3.6, ranking 46th among 325 journals in the Medicine, General & Internal category, placing it in the Q1 zone. PCM has an impact factor of 5.1, ranking 42nd among 189 journals in the Medicine, Research & Experimental category, also in the Q1 zone. AE has received its first impact factor of 1.2, positioning it in the Q4 zone.

 

The Impact Factor (IF) is an important metric measuring the recognition of a journal within the academic community, reflecting the citation frequency of its papers and serving as a key indicator of the journal's academic quality.